Granisetron Fresenius Kabi (Granisetron Hydrochloride)

Granisetron Fresenius Kabi is indicated for the prevention of nausea and vomiting in several clinical situations.

• Chemotherapy‑induced nausea and vomiting (CINV) in adult patients receiving moderately to highly emetogenic regimens.
• Prevention of postoperative nausea and vomiting (PONV) after general anesthesia.
• Adjunct therapy for radiation‑induced nausea when combined with other antiemetics.
• Use in patients who have previously experienced inadequate control with other 5‑HT3 antagonists.
• Management of nausea and vomiting associated with diagnostic procedures that involve contrast agents.
• Supportive care for patients undergoing stem‑cell transplantation who are at risk for emesis.

Adverse events reported with Granisetron Fresenius Kabi span a spectrum from mild, frequently occurring symptoms to rare but potentially life‑threatening conditions. Most patients experience only transient, mild effects, while serious reactions are uncommon and typically related to hypersensitivity or cardiac conduction changes. These events are usually reversible upon discontinuation of therapy.

Common

• Headache
• Constipation or mild abdominal discomfort
• Transient dizziness or light‑headed feeling
• Flushing or warmth sensation
• Fatigue or somnolence
• Nausea (paradoxical)
• Dry mouth

Serious

• Severe allergic reaction such as anaphylaxis or angioedema
• Cardiac arrhythmias, including QT interval prolongation
• Serotonin syndrome when combined with other serotonergic agents
• Seizures
• Severe hypotension
• Liver enzyme elevations

When prescribing Granisetron Fresenius Kabi, clinicians should evaluate patient history and monitor for conditions that could increase the risk of adverse outcomes.

• Assess for known hypersensitivity to granisetron or other 5‑HT3 antagonists.
• Use caution in patients with prolonged QT interval or cardiac conduction disorders.
• Evaluate renal and hepatic function; dose adjustment may be required in severe impairment.
• Consider potential effects on fetal development; use only if the benefit justifies the risk during pregnancy.
• Monitor for signs of serotonin syndrome when combined with serotonergic drugs.
• Avoid use in patients receiving concurrent strong CYP3A4 inhibitors without dose reassessment.

Granisetron Fresenius Kabi may interact with other medications, influencing its efficacy or safety profile. Recognizing these interactions helps optimize therapy.

Avoid

• Concomitant use with other 5‑HT3 receptor antagonists, which can increase the risk of QT prolongation.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may raise granisetron plasma concentrations.
• Monoamine oxidase inhibitors (MAOIs) when combined with serotonergic agents, due to risk of serotonin syndrome.

Use with caution

• Other serotonergic drugs such as SSRIs, SNRIs, or tramadol; monitor for serotonin syndrome.
• Medications that affect cardiac conduction (e.g., antiarrhythmics, certain antipsychotics); observe ECG.
• Diuretics that may cause electrolyte disturbances, potentially augmenting QT interval effects.